Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Unity: Efgartigimod PH20 SC in Primary Sjögren's Disease
NCT06684847Phase 3Active, not recruiting
- Sponsor
- argenx
- Start
- Jan 2025
- Primary completion
- Jul 2027
- Modality
- Antibody Fragments, Therapeutic Enzymes
- Countries
- 39
01
Overview
A Phase 3 trial of efgartigimod alfa + hyaluronidase-qvfc in Sjögren's syndrome, sponsored by argenx. Started Jan 2025; status: active, not recruiting.
02
Drugs
efgartigimod alfa + hyaluronidase-qvfc
03
Conditions
Sjögren's syndrome
Beyond the preview
Go deeper on NCT06684847.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06684847.